S. Louise Phanstiel Purchases 6,100 Shares of Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) Director S. Louise Phanstiel acquired 6,100 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average price of $4.74 per share, with a total value of $28,914.00. Following the completion of the transaction, the director directly owned 183,544 shares in the company, valued at approximately $869,998.56. The trade was a 3.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

S. Louise Phanstiel also recently made the following trade(s):

• On Friday, February 27th, S. Louise Phanstiel purchased 48,000 shares of Myriad Genetics stock. The shares were bought at an average cost of $4.66 per share, with a total value of $223,680.00.
• On Thursday, February 26th, S. Louise Phanstiel purchased 50,407 shares of Myriad Genetics stock. The stock was bought at an average cost of $4.80 per share, with a total value of $241,953.60.

Myriad Genetics Stock Down 5.1%

Shares of NASDAQ:MYGN opened at $4.61 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. Myriad Genetics, Inc. has a 52-week low of $3.76 and a 52-week high of $11.44. The stock’s fifty day simple moving average is $5.61 and its 200-day simple moving average is $6.60. The company has a market capitalization of $431.08 million, a P/E ratio of -1.17 and a beta of 1.90.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.06. Myriad Genetics had a negative return on equity of 6.35% and a negative net margin of 44.38%.The firm had revenue of $209.80 million during the quarter, compared to analysts’ expectations of $207.57 million. During the same quarter last year, the business posted $0.03 EPS. The firm’s quarterly revenue was down .4% compared to the same quarter last year. As a group, equities research analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MYGN has been the topic of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, November 4th. Piper Sandler cut their price target on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a report on Tuesday, November 11th. UBS Group decreased their price objective on Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday. Wells Fargo & Company lowered their price objective on Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Myriad Genetics presently has a consensus rating of “Hold” and a consensus target price of $9.17.

Institutional Trading of Myriad Genetics

Several institutional investors have recently made changes to their positions in MYGN. Hantz Financial Services Inc. raised its position in shares of Myriad Genetics by 1,088.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company’s stock worth $30,000 after buying an additional 3,745 shares during the period. Quarry LP grew its position in Myriad Genetics by 155.6% during the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after acquiring an additional 2,657 shares during the period. EverSource Wealth Advisors LLC increased its stake in Myriad Genetics by 2,333.3% during the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after acquiring an additional 4,480 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Myriad Genetics by 129.6% in the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock worth $31,000 after purchasing an additional 2,818 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Myriad Genetics by 407.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,773 shares of the company’s stock worth $31,000 after purchasing an additional 4,635 shares during the period. 99.02% of the stock is owned by hedge funds and other institutional investors.

More Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Director S. Louise Phanstiel completed multiple open‑market purchases totaling roughly 104,507 shares across Feb. 25–27 (average prices ~ $4.66–$4.80), increasing her stake substantially — a strong signal of insider confidence that can attract buyers. SEC Form 4 filing
• Positive Sentiment: Zacks Research upgraded MYGN from “strong sell” to “hold,” which can reduce model-driven selling and support demand from investors using Zacks screens. Zacks.com
• Neutral Sentiment: Media coverage (TipRanks, MarketBeat, InsiderTrades) amplified the insider activity — this typically increases short‑term volume and retail attention but does not change fundamentals by itself. TipRanks article
• Negative Sentiment: Company updated Q1 FY2026 revenue guidance to $200.0M–$203.0M vs. consensus ~$203.5M and did not provide EPS guidance — the slightly lower top‑line outlook and missing EPS figure create short‑term uncertainty that can pressure the shares. (Company guidance release)
• Negative Sentiment: Recent analyst moves include price‑target cuts (e.g., UBS and Wells Fargo lowering targets to ~$6.00) and mixed ratings — these downward revisions contribute to bearish near‑term sentiment despite some longer‑term analyst support. MarketBeat analyst summary

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.